Locate your nearest distributor

Text search:
Forgot password?

News Archive


08.05.2014 09:30

January–March 2014
  • Net sales grew by 67.5 % compared with Q1/2013
  • Net sales EUR 0.9 million (EUR 0.6 million)
  • Operating result, continuing operations EUR -1.2 million (EUR -1.0 million)
  • Result for the reporting period, continuing operations EUR -1.0 million (EUR -1.0 million)
  • Result for the reporting period, discontinued operations EUR 3.3 million (EUR 0.0 million)
  • Total result for the reporting period EUR 2.2 million (EUR -1.0 million)
  • Net sales from international operations 90.7% (80.1%) of total net sales
  • Equity ratio 91.1% (88.5%)
We focused on supporting our international distributor network, investing in clinical research and preparing for new product launches in business operations during the first quarter 2014.
During the reporting period, we strengthened our existing partnership with Mexican ProGalénika, our distributor partner for Acetium® products. In the first quarter, we extended this cooperation in Mexico to cover the distribution of GastroPanel, having initiated the registration of this product. In April, we also completed the registration of an acetaldehyde-binding capsule in Mexico.
During the reporting period, we signed the following new distributor agreements. Productos Weens SRL is our new distributor of diagnostics products in Peru, Biomed SA is our new diagnostics distributor in Spain, Youlum Biotechnology Co. is our distributor of GastroPanel in Taiwan, and Gulf Orlando Medical Co. is the distributor of Biohit quick tests in Kuwait. We signed a distributing agreement with Korean MoiGen to boost the sales and marketing of Biohit monoclonal antibodies in the IVD industry and research institutes in Korea. We also signed a cooperation agreement with Biospacific Inc. in relation with the distribution of Biohit's antibodies in the diagnostics industry and research communities in the US and Canada.
In April, we launched two clinical trials with Acetium® capsule for prevention of migraine-type headache, assessing the efficacy of Acetium® capsules for a new use. The research projects aim at assessing the efficacy of Acetium® capsules in preventing headache episodes for persons suffering from migraine and cluster/Horton headaches. Both projects are implemented as multicentre studies in partnership with Terveystalo Oy and Aava Medical Centre in six centres across Finland.
In the beginning of May, new Acetium® research results we introduced in the major international meeting for gastroenterologists (Digestive Disease Week) in Chicago. The Congress examined the replicated and confirmed Acetium® capsule results from the studies carried out in Japan and Sweden. In addition, an Italian study, according to which Acetium® capsule seems to improve gastric acid secretion in patients with acid-free stomach (atrophic gastritis) caused by either H. pylori or autoimmune disorder. In relation to the earlier announced study, this is a follow-up phase with a larger number of patients and longer treatment time.
During the reporting period, we introduced to the market a calprotectin test, which enables the differentiation of inflammatory bowel diseases (IBD) from irritable bowel syndrome (IBS) and is suited to the monitoring of the aforementioned conditions. The calprotectin test further extends Biohit's range of diagnostic tests for the gastrointestinal tract.
In April, the GastroPanel validation project was completed for Dynex Technologies' automated DS2 – ELISA processing system. DS2 users can now run the GastroPanel test in accordance with a protocol validated by Biohit."
Biohit Oyj Stock Exchange Release, 8 May 2014 at 9:30 am local time (EEST) (opens in a new window)